A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma

PURPOSE: The treatment of glioblastoma (GBM) poses challenges. The use of immune checkpoint inhibition (ICI) has been disappointing as GBM is characterized by low mutational burden and low T-cell infiltration. The combination of ICI with other treatment modalities may improve efficacy. PATIENT AND M...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Daniel, Qi, Jingjing, Thin, Tin Htwe, Garcia-Barros, Monica, Lee, Brian, Hahn, Mary, Mandeli, John, Belani, Puneet, Nael, Kambiz, Rashidipour, Omid, Ghatan, Saadi, Hadjipanayis, Constantinos G., Yong, Raymund L., Germano, Isabelle M., Brody, Rachel, Tsankova, Nadejda M., Gnjatic, Sacha, Kim-Schulze, Seunghee, Hormigo, Adília
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035521/
https://www.ncbi.nlm.nih.gov/pubmed/36968223
http://dx.doi.org/10.1158/2767-9764.CRC-22-0420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035521/
https://www.ncbi.nlm.nih.gov/pubmed/36968223
http://dx.doi.org/10.1158/2767-9764.CRC-22-0420

Ejemplares similares